Guide · Provider & Vendor
Healthcare AI Procurement: A Practical Framework
How to evaluate, buy, and deploy AI that actually delivers clinical value. A structured approach covering evidence, workflow, safety, and ROI.
The problem with how most organisations buy healthcare AI
Healthcare AI procurement is harder than it looks. Every week, hospitals and imaging networks are approached by AI vendors promising transformative outcomes: shorter read times, missed findings caught, throughput doubled. Most of these tools never make it past pilot. Of the ones that do, a large share fail to deliver on their initial promise.
The cause is not usually the technology. It is the lack of a structured approach to evaluating AI before procurement. Most healthcare organisations rely on a combination of vendor-supplied performance claims, regulatory clearance (CE, UKCA, or FDA), and a brief clinical review. That is enough to satisfy a purchasing committee. It is nowhere near enough to predict whether the tool will actually work in your clinical setting.
Why traditional procurement fails for AI
AI tools do not behave like other medical devices. A new imaging scanner has a defined performance envelope, a stable set of specs, and a predictable integration path. An AI model has:
- Performance that varies with your patient population. A model that achieves 95% sensitivity on a curated academic dataset may drop to 78% on your case mix.
- Workflow impact that depends on how clinicians interact with it. The same model can save time or add friction depending on who is using it and how.
- Value that only shows up over time. Model drift, clinician bypass rates, and real-world accuracy only surface weeks or months into deployment.
Procurement frameworks built for stable products do not catch any of this. Which is why deployed AI tools so often underperform.
A structured framework for healthcare AI procurement
Six stages, run in sequence. Skipping any one of them is where most procurements go wrong.
Strategic scoping
Before evaluating any vendor, scope the problem. What clinical pathway are you trying to improve? What does success look like, quantitatively? Who owns the outcome? Most stalled AI procurements started without a clear answer to any of these questions.
Evidence evaluation
Vendor-supplied evidence is always optimistic. Independent clinical validation is the minimum bar. Look for studies conducted on data that resembles your patient population, peer-reviewed publication rather than marketing whitepapers, performance across demographic subgroups, and reported failure modes. If the vendor’s only evidence is their own internal validation, that is a flag.
Workflow and integration assessment
A technically accurate AI tool that does not fit your workflow will not get used. Evaluate integration with your PACS, EHR, or imaging workstation. Measure the impact on clinician time per case. Understand how the tool behaves when it is wrong, and whether clinicians can override or flag outputs. Simulate the tool running in your actual environment before you sign.
Financial and ROI modelling
Move past the licence cost. Model the total cost of ownership: integration, training, support, ongoing monitoring, and the cost of clinician time for review. Compare against the value side: time savings, diagnostic accuracy improvements, reduced rework, downstream outcome changes. A lot of AI procurement collapses here because nobody quantified the expected return beyond a vendor slide.
Safety and governance review
Every AI tool in clinical use carries risk. Your governance board needs evidence that risk has been identified, documented, and mitigated. Expect the vendor to provide a clinical safety case, hazard identification, transparency on failure modes, and a clear escalation pathway. Missing safety documentation is not a paperwork problem. It is a reason to pause the procurement.
Decision and pilot design
With the evidence collected, make a decision: scale, stop, or redesign. If going ahead, design the pilot carefully with pre-defined success criteria, baseline measurement, and a scheduled review window. Pilots without these collapse into anecdote.
What a complete AI evaluation actually covers
Most procurement processes stop at model metrics. Real-world deployment success depends on four dimensions. A model can ace the first and fail the other three.
Model performance
Sensitivity, specificity, AUC on representative data. Necessary, not sufficient.
Workflow fit
Integration, time per case, clinician bypass rate. Where most deployments fail in practice.
Clinical trust
Adoption, confidence, willingness to rely on the output. Qualitative but measurable.
Measurable ROI
Cost savings, outcome improvements, accountability. What the board ultimately asks about.
Common pitfalls
The traps we see most often in healthcare AI procurement.
Over-relying on vendor demonstrations
A polished demo tells you very little about real-world performance. Insist on a structured pilot with your own data.
Skipping clinician input
The people who use the tool daily must be involved from the start. Their workflow insight is irreplaceable.
Treating regulatory clearance as proof of clinical value
CE, UKCA, and FDA marking means the tool is safe to market. It does not mean it will work in your setting.
Evaluating in isolation
AI tools do not exist in a vacuum. Account for your data quality, existing technology stack, and organisational readiness.
Who should own healthcare AI procurement
No single role can do this alone. A working governance model typically includes:
- Clinical leads who understand the workflow and patient population.
- Informatics or IT leads who own integration and data flow.
- Procurement for commercial and contractual structure.
- An independent evaluator to provide evidence the other three can defend to the board.
The independent role is increasingly the missing piece. Vendor self-validation is not trusted by procurement committees, regulators, or clinicians. Most trusts lack the internal capacity to run rigorous evaluations themselves. That is the gap we exist to fill.
Frequently asked questions
Related guides
Healthcare AI ROI
How to baseline, attribute, and report AI value in a way the board will defend.
Read guideHealthcare AI Readiness
Assessing whether your organisation is set up to deploy AI in the first place.
Read guidePost-Deployment AI Monitoring
Catching drift, bypass, and silent failure after go-live.
Read guideGetting healthcare AI procurement right
Most failed AI deployments can be traced back to decisions made before contracts were signed. A structured evaluation before you buy, covering evidence, workflow, safety, and ROI, is the single biggest lever on whether AI delivers value in your organisation.